ASXL2 Modulates Chromatin Remodeling to Direct Osteogenesis and Multiple Cell Fate in hPDLSCs.

Area of Science:

• Stem Cell Biology
• Epigenetics
• Regenerative Medicine

Background:

• Current strategies for oral and maxillofacial tissue regeneration face limitations.
• Human periodontal ligament stem cells (hPDLSCs) are a promising source for regenerative therapies.
• The epigenetic role of Additional Sex Combs-Like 2 (ASXL2) in hPDLSC osteogenesis is not fully understood.

Purpose of the Study:

• To investigate the epigenetic role of ASXL2 in regulating the osteogenic differentiation of hPDLSCs.
• To elucidate the mechanisms by which ASXL2 influences hPDLSC osteogenesis.
• To explore ASXL2 as a potential therapeutic target for craniofacial regeneration.

Main Methods:

• ASXL2 was knocked down in hPDLSCs using lentiviral vectors.
• Cell proliferation, apoptosis, alkaline phosphatase (ALP) activity, and mineralization were assessed.
• Osteogenic marker expression (RUNX2, ALP, COL1A1, OCN) and global histone modifications (H2AK119ub, H3K27me3, H3K4me3) were analyzed via qPCR, Western blot, and ChIP assays.

Main Results:

• ASXL2 depletion enhanced hPDLSC proliferation and reduced apoptosis.
• However, ASXL2 knockdown significantly impaired osteogenic differentiation, indicated by reduced ALP activity and mineralization.
• This impairment correlated with decreased activating histone mark H3K4me3 and increased repressive marks H2AK119ub and H3K27me3, affecting osteogenic gene expression.

Conclusions:

• ASXL2 plays a critical role in maintaining the osteogenic potential of hPDLSCs through epigenetic regulation.
• Loss of ASXL2 disrupts chromatin accessibility, leading to downregulation of key osteogenic genes via altered histone modification balance.
• ASXL2 is identified as a key epigenetic regulator and a promising therapeutic target for enhancing craniofacial regeneration using hPDLSC-based therapies.